Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-01

Clinical Trial Update: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of RPC1063 in moderate to severe ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RPC1063 (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2021-09-01